Fate Therapeutics, Inc.

NasdaqGM:FATE Stock Report

Market Cap: US$752.1m

Fate Therapeutics Past Earnings Performance

Past criteria checks 0/6

Fate Therapeutics's earnings have been declining at an average annual rate of -20.9%, while the Biotechs industry saw earnings growing at 14.5% annually. Revenues have been growing at an average rate of 47.4% per year.

Key information

-20.9%

Earnings growth rate

-12.4%

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth rate47.4%
Return on equity-43.7%
Net Margin-253.3%
Last Earnings Update31 Dec 2023

Recent past performance updates

Recent updates

Fate Therapeutics, Inc. (NASDAQ:FATE) Held Back By Insufficient Growth Even After Shares Climb 57%

Feb 16
Fate Therapeutics, Inc. (NASDAQ:FATE) Held Back By Insufficient Growth Even After Shares Climb 57%

Fate Therapeutics Update: A Rally Based On Little Increases Near-Term Risks

Jan 26

Fate Therapeutics, Inc.'s (NASDAQ:FATE) Shares Bounce 30% But Its Business Still Trails The Industry

Dec 19
Fate Therapeutics, Inc.'s (NASDAQ:FATE) Shares Bounce 30% But Its Business Still Trails The Industry

Is Fate Therapeutics (NASDAQ:FATE) In A Good Position To Deliver On Growth Plans?

Sep 08
Is Fate Therapeutics (NASDAQ:FATE) In A Good Position To Deliver On Growth Plans?

Benign Growth For Fate Therapeutics, Inc. (NASDAQ:FATE) Underpins Its Share Price

Jun 07
Benign Growth For Fate Therapeutics, Inc. (NASDAQ:FATE) Underpins Its Share Price

Industry Analysts Just Upgraded Their Fate Therapeutics, Inc. (NASDAQ:FATE) Revenue Forecasts By 41%

May 08
Industry Analysts Just Upgraded Their Fate Therapeutics, Inc. (NASDAQ:FATE) Revenue Forecasts By 41%

Is Fate Therapeutics (NASDAQ:FATE) In A Good Position To Invest In Growth?

Apr 17
Is Fate Therapeutics (NASDAQ:FATE) In A Good Position To Invest In Growth?

We Think Fate Therapeutics (NASDAQ:FATE) Needs To Drive Business Growth Carefully

Jan 10
We Think Fate Therapeutics (NASDAQ:FATE) Needs To Drive Business Growth Carefully

Here's Why We're Not Too Worried About Fate Therapeutics' (NASDAQ:FATE) Cash Burn Situation

Sep 22
Here's Why We're Not Too Worried About Fate Therapeutics' (NASDAQ:FATE) Cash Burn Situation

Fate Therapeutics: Yes For Speculators, No For Defensive Investors

Aug 30

Needham initiates Fate coverage Therapeutics on potential of stem cell therapies

Jul 28

Fate Therapeutics names Brian Powl as chief commercial officer

Jun 30

Fate: Possible Speedy FDA Approval Process With RMAT Designation

Jun 03

We're Hopeful That Fate Therapeutics (NASDAQ:FATE) Will Use Its Cash Wisely

Jun 02
We're Hopeful That Fate Therapeutics (NASDAQ:FATE) Will Use Its Cash Wisely

Fate Therapeutics: Slowly Getting To An Attractive Position

Feb 21

We're Not Very Worried About Fate Therapeutics' (NASDAQ:FATE) Cash Burn Rate

Feb 01
We're Not Very Worried About Fate Therapeutics' (NASDAQ:FATE) Cash Burn Rate

Fate Therapeutics: Data Playing Catchup With Valuation

Dec 06

Fate Therapeutics (NASDAQ:FATE) Is In A Good Position To Deliver On Growth Plans

Oct 16
Fate Therapeutics (NASDAQ:FATE) Is In A Good Position To Deliver On Growth Plans

Fate Therapeutics: We Will Wait For Durability Data

Sep 16

Revenue & Expenses Breakdown
Beta

How Fate Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqGM:FATE Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 2364-161790
30 Sep 23106-173850
30 Jun 23119-212880
31 Mar 23137-235830
31 Dec 2296-282840
30 Sep 2269-294800
30 Jun 2268-254740
31 Mar 2263-233660
31 Dec 2156-212570
30 Sep 2155-197510
30 Jun 2148-212430
31 Mar 2140-185390
31 Dec 2031-173340
30 Sep 2018-149300
30 Jun 2013-117280
31 Mar 2011-112260
31 Dec 1911-98240
30 Sep 1910-86210
30 Jun 198-76190
31 Mar 196-72180
31 Dec 185-67160
30 Sep 184-63150
30 Jun 184-57140
31 Mar 184-47120
31 Dec 174-43120
30 Sep 174-38110
30 Jun 174-36110
31 Mar 174-35100
31 Dec 164-33100
30 Sep 164-33100
30 Jun 164-31100
31 Mar 164-30100
31 Dec 152-30100
30 Sep 151-29100
30 Jun 150-2890
31 Mar 150-2790
31 Dec 140-2680
30 Sep 140-2580
30 Jun 140-2580
31 Mar 140-2480
31 Dec 131-2170
30 Sep 132-1960
30 Jun 132-1750
31 Mar 133-1540

Quality Earnings: FATE is currently unprofitable.

Growing Profit Margin: FATE is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: FATE is unprofitable, and losses have increased over the past 5 years at a rate of 20.9% per year.

Accelerating Growth: Unable to compare FATE's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: FATE is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.9%).


Return on Equity

High ROE: FATE has a negative Return on Equity (-43.68%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.